Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Rishabh Mishra

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'

Los,Angeles,-,Jan,8:,Mark,Cuban,At,The,Special

In a strong rebuttal to concerns over pharmaceutical innovation, billionaire Mark Cuban, co-founder of Cost Plus Drugs and Shark Tank fame, argued that slashing pharmacy benefit manager (PBM) fees could paradoxically increase research and development (R&D) funding by allowing manufacturers to earn more.

What Happened: Cuban asserts that brands can earn more by selling directly to his cost-plus model, bypassing the “insane fees” and rebates charged by PBMs.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.